The risk of death after distant metastasis was similar in both treatment groups.
Localized Prostate Cancer
Latest News
Dr. Miles highlights the dilemma of managing PC with BCR after prostatectomy but no visible disease on standard imaging.
Almost 30% of patients will experience recurrence while undergoing EBRT that will require ADT and salvage therapies.
Dr. James showcases an MMAI model to identify benefit from 2nd-generation ARPIs in hr/nm PCa patients from STAMPEDE.
A novel algorithm identifies patients with high-risk non-metastatic PCa who may benefit from second-generation ARPIs.
Dr. Evan Kovac speaks about his pioneering work with extended reality display technology in urologic surgery and education.
The use of MRI-based monitoring can aid in the avoidance of repeat biopsies, and reduce the chances of undergoing surgery.
Prostate Cancer Knowledge Hubs
Curated clinical content based on prostate cancer types, therapies, and technologies
Conference Coverage
At the Oncology Forum, Dr. Sanjay Juneja led a dynamic discussion covering pivotal developments across genitourinary cancers.
Dr. Loïc Djaileb explores the use of RECIP 1.0 criteria with SPECT/CT and the efficacy of this strategy in monitoring mCRPC.
Drs. Tagawa and Marulanda Corzo discuss the use of single time-point SPECT/CT dosimetry for 177Lu-PSMA targeted RLT.
Dr. Nadine Mallak talks about 18F-fluciclovine to detect disease in BCR of prostate cancer when the standard of care fails.
Dr. Miles highlights the dilemma of managing PC with BCR after prostatectomy but no visible disease on standard imaging.
Dr. Kimura shares insights on PSMA PET/CT metrics and their potential role in guiding treatment decisions for mCRPC.
Trending
Interlesional Tumor Response Can Identify Patients With mCRPC With Worse Outcomes After ARPI Therapy
A recent study evaluated the role of PSMA PET/CT in determining patient outcomes based on global tumor response.
Researchers aimed to establish an association between ATEs and germ cell tumors to determine preventative strategies.
Dr. Andrew Armstrong describes a recent MAIC study of enzalutamide versus darolutamide doublet therapy for mHSPC.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.